Mode
Text Size
Log in / Sign up

Twelve SNPs associated with Parkinson's disease-related gray matter volume reduction were identified in meta-analysisGenetic variants linked to brain tissue loss in Parkinson's disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the identification of 12 SNPs associated with gray matter atrophy and 22 SNPs linked to Parkinson's risk and atrophy.

This meta-analysis examines gray matter volume (GMV) reduction and associated genetic variants in patients with Parkinson's disease compared to healthy controls. The study utilized data from 3212 patients with Parkinson's disease and 2056 controls, including UK Biobank data for genome-wide association studies. The analysis identified robust patterns of GMV reduction across the cohort.

Key findings include the identification of 12 significant SNPs associated with Parkinson's disease-related GMV atrophy. Additionally, 22 SNPs were identified as being jointly associated with both Parkinson's disease risk and GMV reduction. Functional enrichment analysis indicated that genes shared between these conditions converge on pathways involved in clathrin-mediated endocytosis and synaptic vesicle recycling.

While the study provides molecular insights and identifies potential therapeutic targets through molecular docking analysis, these targets are not yet confirmed. The results suggest a link between specific genetic variants and the progression of neurodegenerative brain damage. These findings may inform future research into the molecular mechanisms of Parkinson's disease.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the genetic and molecular drivers of neurodegeneration in Parkinson's disease. While previous evidence has explored non-pharmacological interventions like exercise and antioxidants for neuroprotection, and the role of PGE2 signaling in neuroinflammation, this study specifically identifies 12 SNPs associated with gray matter atrophy and 22 SNPs linked to both disease risk and gray matter reduction. These findings provide a molecular basis for the neurodegenerative brain damage observed in the patient population.

Living with Parkinson's disease means facing a condition that gradually affects the brain. Researchers recently analyzed data from over 3,000 patients to better understand how the disease causes physical changes in the brain, specifically the loss of gray matter. Gray matter is the tissue that helps your brain process information.

The study identified 12 specific genetic variants linked to this tissue loss. Even more specifically, they found 22 genetic variants that are linked to both the risk of developing Parkinson's and the reduction of gray matter. These findings help map out exactly where the damage is happening and what genetic factors are involved.

By looking at these shared genes, researchers found they are involved in how cells move materials and recycle parts. While these results are still early and do not offer a new treatment today, they provide a clearer map of the underlying biology. This work helps scientists pinpoint specific targets for future medicines to slow down brain damage.

What this means for you:
Researchers identified specific genetic markers linked to brain tissue loss in patients with Parkinson's disease.

Common questions

What did the study find about the brain in Parkinson's patients?

The study confirmed robust patterns of gray matter volume reduction in people with Parkinson's disease. Gray matter is essential for brain function. The researchers also identified 12 significant genetic variants specifically linked to this loss of brain tissue.

Are there specific genes linked to Parkinson's risk?

Yes, the study identified 22 specific genetic variants that are jointly associated with both the risk of developing Parkinson's disease and the reduction of gray matter in the brain.

How does this research help people with Parkinson's?

While this study does not provide a new treatment, it identifies specific biological pathways and genetic targets. These findings help scientists understand the molecular causes of brain damage, which can help them develop better treatments in the future.

Study Details

Study typeMeta analysis
Sample sizen = 3,212
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by widespread structural brain alterations, yet the specific patterns of brain atrophy and their underlying genetic mechanisms remain incompletely understood. Here, we integrated large-scale neuroimaging meta-analysis with population-scale imaging genetics to systematically characterize the genetic architecture linking gray matter volume (GMV) abnormalities to PD. We first performed a meta-analysis of structural MRI studies comprising 3212 patients with PD and 2056 controls, identifying robust patterns of GMV reduction and assessing differences across medication states. Using these meta-analytically defined regions as imaging phenotypes, we extracted GMV measures from the UK Biobank and conducted genome-wide association analysis (GWAS). This analysis identified 12 significant SNPs associated with PD-related GMV atrophy. Furthermore, we performed pleiotropy analysis and identified 22 SNPs jointly associated with PD risk and GMV reduction. Functional enrichment analyses revealed that these shared genes converge on pathways involved in clathrin-mediated endocytosis and synaptic vesicle recycling. Spatiotemporal transcriptomic profiling further characterized the developmental expression patterns of these genes, while molecular docking analyses suggested potential therapeutic targets. Together, these findings provide a comprehensive characterization of the genetic architecture linking brain structural abnormalities to PD, offering new molecular insights into the mechanisms underlying neurodegenerative brain damage and potential avenues for therapeutic intervention.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.